Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Salarius Pharmaceuticals, Inc. Director's Dealing 2018

Jan 19, 2018

35494_dirs_2018-01-19_6fbada93-1329-478d-ba4f-1187934a0836.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Flex Pharma, Inc. (FLKS)
CIK: 0001615219
Period of Report: 2018-01-17

Reporting Person: Woo Elizabeth (SVP, Investor Relations)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-01-17 Stock Option (right to buy) $3.98 A 50000 Acquired 2028-01-17 Common Stock (50000.0) Direct

Footnotes

F1: The stock option will vest in 48 successive equal monthly installments measured from January 17, 2018.